AHB-137 Receives Breakthrough Therapy Designation from NMPA, Paving the Way for Faster Access to Chronic Hepatitis B Treatment

AHB-137 gains Breakthrough Therapy Designation (BTD) from the NMPA based on Phase 1/Phase2a clinical trial data demonstrating safety and efficacy. BTD...

July 11, 2024 | Thursday | News
Breakthrough Study Links Aging Blood Stem Cells to Increased Inflammatory Diseases

As humans age, hematopoietic stem cells—the immature precursor cells that give rise to all blood and immune cells—accumulate mutations. Some ...

June 12, 2024 | Wednesday | Reports
Roche and Amgen's New Lp(a) Test Receives FDA Breakthrough Device Designation

Approximately one in five people worldwide have elevated Lp(a) levels, putting them at increased risk of cardiovascular diseases including myocardial inf...

May 22, 2024 | Wednesday | News
Roche’s Inavolisib Receives Breakthrough Designation for Advanced Breast Cancer Treatment

The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with pa...

May 21, 2024 | Tuesday | News
Innovent Biologics Receives Breakthrough Therapy Designation for IBI343 in Advanced Gastric Cancer Treatment

Innovent Biologics a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncol...

May 07, 2024 | Tuesday | News
SS Innovations' SSi Mantra System Completes First Infant Pyeloplasty in India

SS Innovations International, Inc., a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible t...

April 30, 2024 | Tuesday | News
Avistone Biotechnology's Vebreltinib Granted Historic Approval for Glioma Treatment by Chinese NMPA, Paving the Way for Targeted Therapy Breakthroughs in 2024

Beijing Avistone Biotechnology Co., Ltd. (also referred to as Avistone Biotechnology or Avistone), an innovative biotechnology company focused on precision...

April 26, 2024 | Friday | News
Breakthrough Cardiac Study Reveals Long-Term Impact on Post-Transplant Survival: A 2-Year Clinical Investigation Advancing Heart Preservation

Paragonix Technologies, Inc., a pioneer in organ transplant technologies and services, announces the annual release of the latest GUARDIAN-Heart Clinical R...

April 14, 2024 | Sunday | Reports
Thermo Fisher Scientific Launches Animal-Free Formula for Cell Therapy Production Scale-Up

  Thermo Fisher Scientific Inc., the world leader in serving science, has introduced the Gibco™ CTS™ OpTmizer™ One Serum-Free Mediu...

April 12, 2024 | Friday | News
Denovo Biopharma's Liafensine Shows Promise in Phase 2b Trial for Treatment-Resistant Depression

Denovo Biopharma LLC (Denovo), a pioneer in applying precision medicine to the development of innovative drugs, today announced positive results for its bi...

April 09, 2024 | Tuesday | News
LISCure Biosciences' LB-P8 Granted Fast Track Designation by FDA for Primary Sclerosing Cholangitis Treatment

LISCure Biosciences, a leading clinical-stage biopharmaceutical company focused on discovering and developing innovative microbiome-based therapies, a...

April 01, 2024 | Monday | News
Orchard Therapeutics Achieves Landmark FDA Approval for Lenmeldy™, Pioneering Gene Therapy for Early-onset Metachromatic Leukodystrophy

Orchard Therapeutics, now under the stewardship of Kyowa Kirin, announces a historic milestone as the U.S. Food and Drug Administration (FDA) grants approv...

March 19, 2024 | Tuesday | News
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company specializing in endocrine diseases and tumors, revealed encouraging...

March 13, 2024 | Wednesday | News
BRUKINSA Breakthrough: First BTK Inhibitor Approved for Five Oncology Indications Including Follicular Lymphoma

BRUKINSA is the first and only BTK inhibitor approved across five oncology indications and the first and only approved in follicular lymphoma Approv...

March 08, 2024 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in